A new more detailed stratification of low responders to ovarian stimulation From a poor ovarian response to a low prognosis concept

Wednesday, June 1, 2016

Authors:
Poseidon Group (Patient-Oriented Strategies Encompassing Individualized Oocyte Number), Carlo Alviggi, M.D., Ph.D., Claus Y.…

Read More

Intercycle variability of the ovarian response in patients undergoing repeated stimulation with corifollitropin alfa in a gonadotropin releasing hormone antagonist protocol

Tuesday, September 29, 2015
The considerable variability in individual ovarian responses observed between repeated IVF cycles conducted using the same protocol were not explained by baseline serum follicle-stimulating hormone concentrations or antral follicle count.

Read More

Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization

Monday, June 29, 2015
Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surge in in vitro fertilization.

Read More

Long term effects of repeated superovulation on ovarian structure and function in rhesus monkeys

Wednesday, July 9, 2014
A rhesus monkey model indicates that repeated controlled ovarian hyperstimulation could potentially affect the development and function of ovarian cells in the long term.

Read More

Preterm births multiples and fertility treatment Recommendations for changes to policy and clinical practices

Wednesday, June 25, 2014
Each year nearly one in eight infants in the United States is born preterm. Preterm birth places babies at increased risk for death, health problems including long-term neurological disabilities, and extended time in the hospital.

Read More

A novel delayed start protocol with gonadotropin releasing hormone antagonist improves outcomes in poor responders

Wednesday, April 30, 2014
The delayed-start protocol improves ovarian response in poor responders by enhancing, promoting, and synchronizing follicle development.

Read More

Progesterone elevation does not compromise pregnancy rates in high responders a pooled analysis of in vitro fertilization patients treated with recombinant FSH GnRH antagonist in six trials

Wednesday, November 27, 2013
Incidence of elevated P increases with ovarian response, and elevated P (>1.5 ng/mL) is independently associated with a decreased chance of pregnancy in low to normal, but not high, responders.

Read More

Effective method for emergency fertility preservation random start controlled ovarian stimulation

Wednesday, November 27, 2013
Random-start controlled ovarian stimulation (COS) protocols are as effective as conventional-start COS in fertility preservation and provide a significant advantage by decreasing the total time for embryo/oocyte cryopreservation.

Read More

Transforming growth factor β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation

Wednesday, July 31, 2013
Increased transforming growth factor-b1 and decreased levels of its receptor, soluble endoglin are found in women with polycystic ovarian syndrome (PCOS) and may be implicated in PCOS pathogenesis and its increased risk for ovarian hyperstimulation.

Read More

Cost effectiveness comparison between pituitary down regulation with a gonadotropin releasing hormone agonist short regimen on alternate days and an antagonist protocol for assisted fertilization treatments

Tuesday, April 30, 2013
Although the controlled ovarian stimulation protocol with short GnRH agonist in alternate days may lower the cost of an individual IVF cycle, it requires more cycles to achieve pregnancy.

Read More

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis

Wednesday, May 30, 2012
The administration of human chorionic gonadotropin in the early and late follicular phase in controlled ovarian stimulation shows results similar to the conventional regimens, with the advantage of decreasing the doses of follicle-stimulating hormone.

Read More

Translate »